News
March 2, 2020: Longhorn Vaccines & Diagnostics Encouraged by FDA to Help Solve Coronavirus Testing Bottleneck by Teaming PrimeStore MTM® with Diagnostic Developers
April 23, 2019: PrimeStore® MTM opens Sputum-free Molecular Screening for M. tuberculosis Infection
September 24, 2018: Game Changing Tuberculosis Assay Validated for Illumina's MiSeq® Platform
March 22, 2018: World TB Day 2018: US Food and Drug Administration Clears PrimeStore® MTM, an Important New Device
March 21, 2018: Longhorn Vaccines and Diagnostics LLC receives de novo clearance by the U.S. Food and Drug Administration for PrimeStore® Molecular Transport Medium establishing a new class of microbial nucleic acid stabilization devices for molecular testing
July 20, 2016: Tuberculosis Detection With Cepheid MTB Test Improved By Longhorn's Sample Transport Medium
May 22, 2017: PrimeStore® Molecular Transport Medium Aiding Laboratories Tracking H7N9 Avian Influenza
Nov. 2, 2015: Longhorn Vaccines and Diagnostics LLC's PrimeSuite TB™ products included in the 2015 UNITAID Tuberculosis Diagnostics Technology and Market Landscape
Feb. 24, 2010: Longhorn Vaccines and Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM)
